We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Final ICH Pharmacovigilance Guidance Focuses on Early Postmarketing Period
Final ICH Pharmacovigilance Guidance Focuses on Early Postmarketing Period
March 31, 2005
Following on the heels of other recent guidances intended to help firms better monitor drug-safety issues, the FDA released a final guidance March 31 that describes a method for summarizing identified drug risks, particularly those found early in the postmarketing period.